Table 2 Prevalence of resistance to Rifampicin and MDR-TB in smear-positive patients with pulmonary TB, Djibouti nationwide drug-resistance survey, 2014–2015.

From: Culture and Next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: results from the first national survey

 

New cases (n = 301)

Previously treated cases (n = 66)

Total (n = 367)

n

% (95%CI)

n

% (95%CI)

n

% (95%CI)

Rifampicin-resistance

14

4.7% (2.8; 7.7)

23*

34.9% (24.5; 46. 9)

37

10.1% (7.4; 13.6)

MDR-TB

14

4.7% (2.8; 7.7)

20

30.8% (20. 9; 42.8)

34

9.3% (7.2; 14.6)

  1. *Isoniazid susceptibility testing was available for 22 out of 23 rifampicin resistant previously treated TB patients.
Back to article page